BRAF and lung carcinoma: Currently, Dabrafenib and Trametinib are recommended for patients with a BRAF-V600E mutation, which was the only mutation detected in all the 28 cases (3% of the total tested) in our series [5]; this will surely improve the prognostic role of BRAF mutations in lung cancer in the future.